

HBD East 2021 Think Tank Meeting

Date: Thursday, January 13th, 2022 (US), Friday, January 14th, 2022 (JP)

Symposium Location: Online (Zoom)

Host: MHLW/PMDA/JFMDA

Language: Japanese and English (Translation from Japanese to English, from English to Japanese)

Day 1: January 13th (US) and January 14th (JP)

Time	Agenda items
3:00 PM (PST), 6:00 PM (EST), 8:00 AM (JST)	(1) Welcome speech (5 min each)
	Chair: Masahiro TAKAHATA (MHLW)
	1) MHLW : Fumi YAMAMOTO, Councilor 2) PMDA : Yasuhiro FUJIWARA, Chief Executive 3) US FDA : Bram Zuckerman, Office Director 4) JFMDA : Shugo SUMIYOSHI, Vice Chairman
3:20 PM (PST), 6:20 PM (EST), 8:20 AM (JST)	(2) Keynote Lecture (10 min)
	Chair: Shin IWAMOTO (PMDA)
	Regulatory Innovation for Safe and Early Access to Medical Devices in Japan Hidehito SEKINO (MHLW)
	(3) Update of HBD activity (10 min each)
	1) HBD Steering Committee : Erika NORO (PMDA) 2) HBD for Children : Kalkidan Molla (FDA)
3:50 PM (PST), 6:50 PM (EST), 8:50 AM (JST)	(4) Rethinking of the New Style of Global Clinical Trial
	Chair: Atsushi TAMURA (PMDA), Yuka SUZUKI (Tohoku University), Neal Fearnott (COOK Medical)
	<Section1: Clinical Design> 1) The outlook for Patient Involvement in Medical Device Development ~Japanese Regulatory View~ (10 min) Takeshi SHIBA (PMDA) 2) The outlook for Patient Involvement in Medical Device Development ~US Regulatory View~ (10 min) Michelle Tarver (FDA) 3) Panel Discussion (15 min)

<p>3:50 PM (PST), 6:50 PM (EST), 8:50 AM (JST)</p>	<p>Panelist: Aaron Lottes (Purdue University), Kate Stohlman (Corvia Medical), Moe OHASHI (PMDA), Takahiro UCHIDA(JOMDD)</p> <p>Talking point: What are the challenges and opportunities for using patient-oriented data for global regulatory purposes?</p>
<p>4:25 PM (PST), 7:25 PM (EST), 9:25 AM (JST)</p>	<p>(4) Rethinking of the New Style of Global Clinical Trial</p>
	<p>Chair: Atsushi TAMURA (PMDA), Yuka SUZUKI (Tohoku University), Neal Fearnot (COOK Medical)</p>
	<p>< Section2: GCP Inspection ></p> <p>1) Considerations for GCP inspections of global clinical trials (10 min) Kazuo KAWAHARA (Boston Scientific)</p> <p>2) Balancing reliability assurance and optimization GCP inspection based on trends of conducting global clinical trial. (10 min) Takashi YOSHITANI (PMDA)</p> <p>3) Panel Discussion (15 min) Panelist: Adam Donat (FDA), US academia, US Industry Talking point: What lessons from conducting clinical studies during the COVID pandemic can be applied to facilitate future global clinical trials?</p>
<p>5:00 PM (PST), 8:00 PM (EST), 10:00 AM (JST)</p>	<p>(5) “How to promote the development of pediatric medical devices.” ~HBD for children~ (60min)</p>
	<p>Chair: Satoshi YASUKOCHI (Jisenkai Aizawa Hospital), Nicole Gillette (FDA), Kisaburo SAKAMOTO (Shizuoka Children’ s Hospital)</p>
	<p>1) Report from Japanese national grant research to promote the efficient development of pediatric medical devices (10 min) Wakako SAKAMOTO (PMDA)</p> <p>2) Importance of Global development ~Experience from HBD for children’ s POC, Harmony valve~ (10min) Declan Dineen (Medtronic)</p> <p>3) Importance of Global development ~Standardization of definitions ~ (10min) Shintaro NEMOTO (Osaka Medical and Pharmaceutical University)</p> <p>4) Discussion (30 min) Panelist: Frank Ing (UC Davis Children’ s Hospital), Hideshi TOMITA (Showa University) and Takeharu KOBAYASHI (DAIKEN MEDICAL) Talking point: What areas of collaboration or standardization would be most beneficial to further encourage pediatric device development?</p>
<p>6:00 PM (PST), 9:00 PM (EST), 11:00 AM (JST)</p>	<p>Closing remarks (5 min) Yuka SUZUKI (Tohoku University)</p>